The FDA enforcement report lists a Class II recall of compounded semaglutide/cyanocobalamin 9/2 mg/mL injectable syringes from Carolina Infusion, LLC. The stated reason is lack of assurance of sterility, related to the formulation's use of bacteriostatic water and to processing equipment. The recall is ongoing, and related entries cover other strengths and compounded tirzepatide.
A Class II recall indicates a product that may cause temporary or medically reversible harm, or where serious harm is remote. Compounded incretin products are not licensed medicines, and combining them with vitamin B12 has no licensed basis. The products are US-compounded; the prescribing lesson is to know what a patient is actually injecting.
- Ask patients on weight-loss injections whether the product is licensed or compounded.
- Remember that compounded semaglutide doses may not match licensed products.
- Ask about injection-site infection and fever in users of compounded injections.
- Report suspected reactions to compounded products through pharmacovigilance channels.
Why it matters
Unlicensed incretin products are widespread, and their quality is invisible from the consulting room.
Don't overread it
A sterility-assurance recall is not evidence of patient harm or of a problem with licensed semaglutide.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free